Litcius/Paper detail

A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization

Juliane S. Lanza, Sonja Vučen, Olivia Flynn, Agnese Donadei, Sandrine Cojean, Philippe M. Loiseau, Ana Paula Fernandes, Fréderic Frézard, Anne Moore

2020International Journal of Pharmaceutics43 citationsDOIOpen Access PDF

Topics & Concepts

Cationic liposomeCpG OligodeoxynucleotideLiposomeAntigenAdjuvantImmunizationLeishmania donovaniReactogenicityLeishmania mexicanaCutaneous leishmaniasisMedicineLeishmaniasisImmunologyLeishmaniaVirologyVisceral leishmaniasisBiologyParasite hostingGenetic enhancementGeneComputer scienceGene expressionBiochemistryDNA methylationWorld Wide WebResearch on Leishmaniasis StudiesToxin Mechanisms and ImmunotoxinsTransgenic Plants and Applications
A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization | Litcius